Nigeria - engelsk - NAFDAC (National Agency for Food and Drugs Administration and Control)

artesunate 200mg.mefloquine 250mg

Nigeria - engelsk - NAFDAC (National Agency for Food and Drugs Administration and Control)

artesunate 200mg, mefloquine 250mg

Nigeria - engelsk - NAFDAC (National Agency for Food and Drugs Administration and Control)

artesunate 200mg,mefloquine 250mg

Nigeria - engelsk - NAFDAC (National Agency for Food and Drugs Administration and Control)

artesunate 200mg,mefloquine 250mg

Nigeria - engelsk - NAFDAC (National Agency for Food and Drugs Administration and Control)

artesunate 200mg.mefloquine 250mg

Nigeria - engelsk - NAFDAC (National Agency for Food and Drugs Administration and Control)

artesunate 200mg + mefloquine 250mg

Malaysia - engelsk - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novartis corporation (malaysia) sdn. bhd. - artemether; lumefantrine -

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - lumefantrine; artemether -

Canada - engelsk - Health Canada

sanofi-aventis canada inc - primaquine phosphate - tablet - 26.3mg - primaquine phosphate 26.3mg - antimalarials

USA - engelsk - NLM (National Library of Medicine)

novartis pharmaceuticals corporation - artemether (unii: c7d6t3h22j) (artemether - unii:c7d6t3h22j), lumefantrine (unii: f38r0jr742) (lumefantrine - unii:f38r0jr742) - artemether 20 mg - coartem tablets are indicated for treatment of acute, uncomplicated malaria infections due to plasmodium falciparum (p. falciparum) in patients 2 months of age and older with a bodyweight of 5 kg and above. coartem tablets have been shown to be effective in geographical regions where resistance to chloroquine has been reported [see clinical studies (14.1) ]. limitations of use: - coartem tablets are not approved for patients with severe or complicated p. falciparum malaria. - coartem tablets are not approved for the prevention of malaria. hypersensitivity known hypersensitivity to artemether, lumefantrine, or to any of the excipients of coartem tablets [see adverse reactions (6.2)] . strong cyp3a4 inducers coadministration of strong inducers of cyp3a4 such as rifampin, carbamazepine, phenytoin, and st. john’s wort with coartem tablets can result in decreased concentrations of artemether and/or lumefantrine and loss of antimalarial efficacy [see warnings and precautions (5.3), drug interactions (7.1), and cl